PPMonitor checks laboratory air quality

Published: 12-Apr-2010
Design & Build HVAC Regulatory

Enables effective and flexible management of indoor air quality

PPM Technology’s wireless IAQ profile PPMonitor enables simple, effective and flexible management of the indoor air environment of a laboratory or cleanroom.

The PPMonitor, from the Caernarfon, Wales firm, can continuously detect, measure and record temperature, humidity, formaldehyde, nitrogen dioxide, carbon monoxide, carbon dioxide, sulphur dioxide, ozone, ammonia and TVOCs.

The device incorporates a variety of advanced gas sensor technologies to monitor the target gases including NDIR, PID and electrochemical sensors.

The wireless units communicate via the Zigbee wireless mesh network, which can be extended by adding repeater nodes or additional PPMonitor or Mini PPMonitor units. Each unit can be configured with unique sensor specifications if required, allowing complete monitoring of the cleanroom air environment.

PPMonitor Units can be wirelessly connected to a Building Management System, in which BMS software allows the entire wireless system to be managed from a single PC. The BMS can activate and control air conditioning and ventilation systems; it can also turn on/off heating and trigger building alarms, if required.

All recorded data is stored automatically with dedicated software, which enables the data to be viewed graphically and produces reports and statistical data. Analysis of the recorded data over time allows for more efficient management of resources and energy.

See more

You may also like

Regulatory

Abzena advances immunogenicity risk assessment in biologic drug development

Read more
New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins

Trending Articles

  1. Piramal Pharma Solutions awards Riverview and Digwal for patient centricity Two sites recognised for innovative initiatives that put patients first
  2. Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
  3. NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
  4. FDA US agent services backed by regulatory expertise Helping medical device companies achieve smooth US market entry
  5. FDA grants Breakthrough Therapy designation to BeOne Medicines' sonrotoclax The designation comes after positive early results of a Phase I/II study in patients with relapsed or refractory mantle cell lymphoma, with BeOne aiming to participate in Project Orbis programme to advance global access

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Regulatory

Abzena advances immunogenicity risk assessment in biologic drug development

New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins
Regulatory

Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I

Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory

NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case

The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Regulatory

Piramal Pharma Solutions awards Riverview and Digwal for patient centricity

Two sites recognised for innovative initiatives that put patients first
Manufacturing

FDA US agent services backed by regulatory expertise

Helping medical device companies achieve smooth US market entry
Manufacturing

What to expect from a regulatory inspection

NSF’s expert guide outlines key expectations, common pitfalls and strategies for lasting inspection readiness
Subscribe now